Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Autoimmune Diseases
Pharma
Novartis' BTK drug clears ph. 3 in MS sans liver safety signal
The promise of BTK inhibitors in multiple sclerosis was undercut by recurring liver toxicity signals, which previously triggered FDA clinical holds.
Angus Liu
Sep 1, 2026 11:10am
Argenx preps next potential Vyvgart nod after ph. 3 win
Aug 17, 2026 10:52am
EU regulators offer post-mortem of Tavneos withdrawal decision
Aug 14, 2026 11:04am
Roche's Enspryng cuts MOGAD relapse risk by 68% in phase 3
Apr 21, 2026 10:15am
Roche heads to regulators with new autoimmune win for Gazyva
Feb 17, 2026 10:15am
Novartis to seek full IgAN nod for Vanrafia despite ph. 3 miss
Feb 13, 2026 10:52am
